Terms
Assay methods, evidence tiers, receptor pharmacology, and catalogue terminology.
- Certificate record
Retatrutide source documentation identifies laboratory sample RET-317, the analysis provider, method, report date, chromatographic purity, and verification code.
Document lookup →- HPLC
High-performance liquid chromatography, an analytical technique used to separate and measure components in a sample. Its result must be interpreted with the stated method and limitations.
FDA analytical-method guidance ↗- Mass spectrometry
An analytical technique that measures mass-to-charge ratios and can support identity analysis when used with an appropriate method.
FDA analytical-method guidance ↗- Preclinical
Research conducted before human clinical testing, commonly in laboratory or animal models. Preclinical findings do not establish effectiveness in people.
NCBI preclinical research overview ↗- Research profile
A source-led overview of a compound, its research context, evidence level, limitations, and regulatory notes, kept distinct from the product offer.
Evidence library →- Agonist
Receptor binding that activates receptor signalling.
IUPHAR/BPS Guide to Pharmacology ↗- Antagonist
Receptor binding that blocks or reduces agonist signalling.
IUPHAR/BPS Guide to Pharmacology ↗- EC50
An assay potency measure at which a response reaches half of the defined maximum under stated conditions.
IUPHAR/BPS Guide to Pharmacology ↗- IC50
An assay potency measure at which an inhibitory effect reaches half of the defined maximum under stated conditions.
IUPHAR/BPS Guide to Pharmacology ↗- Kd
An equilibrium binding measure used to describe ligand–receptor affinity under stated conditions.
IUPHAR/BPS Guide to Pharmacology ↗- Receptor selectivity
Relative activity at one receptor compared with activity at other receptors in the stated assay system.
IUPHAR/BPS Guide to Pharmacology ↗- Incretin
Gut-derived hormone signalling associated with glucose-dependent insulin secretion.
IUPHAR/BPS Guide to Pharmacology ↗- Secretagogue
A compound class that stimulates secretion from a cell or gland.
IUPHAR/BPS Guide to Pharmacology ↗- Phase 1 / 2 / 3
Clinical trial stages that progress from initial human study through larger efficacy and safety evaluation.
FDA clinical-research overview ↗- Estimand
The precise treatment effect that a clinical trial aims to estimate.
ICH E9(R1) estimands guideline ↗- Primary endpoint
The prespecified outcome that defines the main trial question.
ICH E9 statistical-principles guideline ↗- Placebo-controlled
A trial design that compares the investigational intervention with a placebo control.
ICH E10 control-group guideline ↗- In vitro / in vivo
Experimental work conducted outside a living organism / experimental work conducted in a living organism.
NCBI preclinical research overview ↗- Half-life
The time required for a measured amount to decline by one half under stated conditions.
FDA clinical-pharmacology guidance ↗- Analogue
A molecule designed or selected for structural similarity to another molecule.
IUPHAR/BPS Guide to Pharmacology ↗- Peptide fragment
A sequence shorter than the full-length parent peptide.
Malinda, Goldstein & Kleinman, FASEB Journal, 1997 ↗- Lyophilisation
A freeze-drying process that removes water from a frozen material by sublimation under reduced pressure.
FDA lyophilized-product guidance ↗